132 related articles for article (PubMed ID: 22172011)
1. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex.
Khuntawee W; Rungrotmongkol T; Hannongbua S
J Chem Inf Model; 2012 Jan; 52(1):76-83. PubMed ID: 22172011
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the binding behavior of flavonoids to the cyclin dependent kinase 6/cyclin D complex.
Zhang J; Zhang L; Xu Y; Jiang S; Shao Y
PLoS One; 2018; 13(5):e0196651. PubMed ID: 29715320
[TBL] [Abstract][Full Text] [Related]
3. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.
Tsitsanou KE; Hayes JM; Keramioti M; Mamais M; Oikonomakos NG; Kato A; Leonidas DD; Zographos SE
Food Chem Toxicol; 2013 Nov; 61():14-27. PubMed ID: 23279842
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
Lu H; Chang DJ; Baratte B; Meijer L; Schulze-Gahmen U
J Med Chem; 2005 Feb; 48(3):737-43. PubMed ID: 15689157
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for CDK6 activation by a virus-encoded cyclin.
Schulze-Gahmen U; Kim SH
Nat Struct Biol; 2002 Mar; 9(3):177-81. PubMed ID: 11828325
[TBL] [Abstract][Full Text] [Related]
6. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
Sims PA; Wong CF; McCammon JA
J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
[TBL] [Abstract][Full Text] [Related]
7. Reducing CDK4/6-p16(INK4a) interface. Computational alanine scanning of a peptide bound to CDK6 protein.
Villacañas O; Rubio-Martinez J
Proteins; 2006 Jun; 63(4):797-810. PubMed ID: 16508961
[TBL] [Abstract][Full Text] [Related]
8. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
9. Reduced state transition barrier of CDK6 from open to closed state induced by Thr177 phosphorylation and its implication in binding modes of inhibitors.
He H; Xu J; Xie W; Guo QL; Jiang FL; Liu Y
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):501-512. PubMed ID: 29108955
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new small-molecule cyclin-dependent kinase 6 inhibitors through computational approaches.
Luo X; Zhao Y; Tang P; Du X; Li F; Wang Q; Li R; He J
Mol Divers; 2021 Feb; 25(1):367-382. PubMed ID: 32770459
[TBL] [Abstract][Full Text] [Related]
11. Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6.
Yousuf M; Shamsi A; Khan P; Shahbaaz M; AlAjmi MF; Hussain A; Hassan GM; Islam A; Rizwanul Haque QM; Hassan MI
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429317
[TBL] [Abstract][Full Text] [Related]
12. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition.
Lu H; Schulze-Gahmen U
J Med Chem; 2006 Jun; 49(13):3826-31. PubMed ID: 16789739
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.
de Azevedo WF; Canduri F; da Silveira NJ
Biochem Biophys Res Commun; 2002 Apr; 293(1):566-71. PubMed ID: 12054639
[TBL] [Abstract][Full Text] [Related]
14. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
[TBL] [Abstract][Full Text] [Related]
15. GRID and docking analyses reveal a molecular basis for flavonoid inhibition of Src family kinase activity.
Wright B; Watson KA; McGuffin LJ; Lovegrove JA; Gibbins JM
J Nutr Biochem; 2015 Nov; 26(11):1156-65. PubMed ID: 26140983
[TBL] [Abstract][Full Text] [Related]
16. The effect of the skeleton structure of flavanone and flavonoid on interaction with transferrin.
Zhang XF; Han RM; Sun XR; Li GY; Yang QF; Li Q; Gai W; Zhang M; Chen L; Yang G; Tang YL
Bioorg Med Chem Lett; 2013 Dec; 23(24):6677-81. PubMed ID: 24239187
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol binds to duplex DNA.
Bible KC; Bible RH; Kottke TJ; Svingen PA; Xu K; Pang YP; Hajdu E; Kaufmann SH
Cancer Res; 2000 May; 60(9):2419-28. PubMed ID: 10811119
[TBL] [Abstract][Full Text] [Related]
18. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
19. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells.
Yin F; Giuliano AE; Law RE; Van Herle AJ
Anticancer Res; 2001; 21(1A):413-20. PubMed ID: 11299771
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase.
Kaiser A; Nishi K; Gorin FA; Walsh DA; Bradbury EM; Schnier JB
Arch Biochem Biophys; 2001 Feb; 386(2):179-87. PubMed ID: 11368340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
